DBT-BIRAC supported ZyCoV-D developed by Zydus Cadila Receives Emergency Use Authorization
Zydus Cadila received Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) today, i.e. 20/08/2021, for ZyCoV-D, the world’s first and India’s indigenously developed DNA-based vaccine for COVID-19 to be administered in humans, including children and adults 12 years and older. ZyCoV-D was developed in collaboration with the Department...
Covaxin works against Delta Plus:
In the study of efficacy of the Covaxin vaccine. They have found that despite a slight reduction in neutralisation antibody titres, the vaccine remains effective against the Delta, AY.1 (Delta Plus), and B.1.617.3 variants.
Read More
REASONS FOR NOT TAKING THE VACCINES ACROSS DIFFERENT COUNTRIES
This stacked area chart represents the reasons for not taking vaccines among participants from 11 countries.
Phone and online survey about vaccine hesitancy were conducted in 11 countries, out of which 9 are Low-middle income countries.
Concerns about side-effects has the biggest overall reason for vaccine hesitancy. More than half surveyees from Uganda were worried about...
CDSCO expert panel recommends nod to study on mixing doses of Covaxin, Covishield
An expert panel of India’s central drug authority recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a clinical trial of mixing of two COVID-19 vaccines — Covaxin and Covishield.
The panel also recommended giving approval to Bharat Biotech for carrying out a study on interchangeability of its Covaxin and the under-trial...
Effectiveness of COVID-19 vaccines against the Delta variant
This case-control study compares the effectiveness of Pfizer-BioNTech (BNT162b2) and Covishield (ChAdOx1 nCoV-19) Vaccines against the Alpha and Delta variants.
Both the vaccines showed a rise in its effectiveness after administration of Dose 2.
BNT162b2 has 93.7% and 88%, while ChAdOx1 nCoV-19 shows 74.5% and 67% effectiveness against Alpha and Delta variants,...